TrialDiabetes, obesity & metabolism2018

Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.

Ryuzo Kawamori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.